文献速递肾癌与肾肿瘤

推迟性减瘤性肾切除术在转移性透明细胞肾细胞癌中的汇总分析

Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
PubMed 文献 · Eur Urol Oncol · 2020-01-16

本研究汇总前瞻性试验数据,比较先行VEGFR-TKI后行减瘤性肾切除术(推迟CN)与先行CN后行VEGFR-TKI(前期CN)的结局。在MSKCC中危组中,推迟CN组144例与前期CN组131例相比,推迟CN组OS为33.0个月(95%CI 25.0-51.0),前期CN组为22.8个月(95%CI 17.9-30.6),HR 0.72(95%CI 0.52-0.996),p=0.047。结论提示在MSKCC中危患者中,无疾病进展时推迟CN的策略OS优于前期CN,值得进一步个体数据汇总分析。

要点

  • MSKCC中危转移性透明细胞肾癌患者中,推迟CN组OS为33.0个月,前期CN组为22.8个月
  • 推迟CN组与前期CN组比较HR 0.72(95%CI 0.52-0.996),p=0.047
  • 研究为回顾性比较和亚组分析,需个体患者数据进一步验证

核心结论

  • 在MSKCC中危患者中,无进展时推迟减瘤性肾切除术的策略OS优于前期减瘤性肾切除术,并与CARMENA已发表试验数据相比具有优势。

研究设计与样本

  • 汇总前瞻性试验中推迟CN策略的数据,与前期CN的回顾性数据集进行比较,患者治疗时间为2006年至2016年。
  • MSKCC中危组中,推迟CN组144例,前期CN组131例。

主要发现

  • 推迟CN组中位OS为33.0个月(95%CI 25.0-51.0),前期CN组为22.8个月(95%CI 17.9-30.6)。
  • 推迟CN与前期CN比较的风险比为0.72(95%CI 0.52-0.996),p=0.047。

临床怎么用

  • 在MSKCC中危转移性透明细胞肾癌患者中,可考虑先行VEGFR-TKI治疗,无疾病进展者再行推迟性减瘤性肾切除术。

局限性

  • 研究为回顾性比较数据。
  • 研究为亚组分析。
  • 前期CN队列缺乏意向性治疗数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancer du Rein Métastatique Nephrectomie et Antiangiogéniques (CARMENA) concluded that sunitinib alone is not inferior to cytoreductive nephrectomy (CN) followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in patients with metastatic renal cell carcinoma. It remains uncertain whether deferred CN is beneficial in this setting. OBJECTIVE: The aim of this study was to compare outcome in patients treated with presurgical VEGFR-TKI followed by CN (deferred CN) with that in patients receiving CN followed by VEGFR-TKI (upfront CN). DESIGN, SETTING, AND PARTICIPANTS: Pooled data from prospective trials in which a strategy of deferred CN in the absence of disease progression was investigated were compared with a retrospective dataset of upfront CN. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) in the Memorial Sloan-Kettering Cancer Center (MSKCC) intermediate-risk group. RESULTS AND LIMITATIONS: Patients were treated between 2006 and 2016. In the MSKCC intermediate-risk group, 144 patients with a strategy of deferred CN after systemic therapy were compared with 131 patients treated with upfront CN. OS in the deferred cohort was 33.0 mo (95% confidence interval [CI] 25.0-51.0) compared with 22.8 mo (95% CI 17.9-30.6) after upfront CN (hazard ratio 0.72 [95% CI 0.52-0.996], p = 0.047). This study is limited by retrospective comparison of data, subgroup analysis, and a lack of intention-to-treat data for the upfront CN cohort. CONCLUSIONS: In MSKCC intermediate-risk patients, a strategy of deferred CN in the absence of progression yields OS, which compares favourably with upfront CN and published trial data from CARMENA. This warrants a formal individual patient data analysis of CARMENA, SURTIME, and single-arm prospective studies to define the role and timing of deferred CN in intermediate-risk patients. PATIENT SUMMARY: In this study, we report outcomes in patients with metastatic renal cell cancer treated with targeted therapy followed by nephrectomy, which compared favourably with nephrectomy followed by targeted therapy and results from published studies.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. de Bruijn R, Wimalasingham A, Szabados B, et al. Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data. Eur Urol Oncol. 2020. PMID: 31956080. doi:10.1016/j.euo.2019.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。